Bronchiectasis in Asia: a review of current status and challenges.

Recent bronchiectasis studies from large-scale multinational, multicentre registries have demonstrated that the characteristics of the disease vary according to geographic region. However, most perspectives on bronchiectasis are dominated by data from Western countries. This review intends to provide an Asian perspective on the disease, focusing on the established registries in India, Korea and China. Asian patients with bronchiectasis are less likely to show female predominance and experience exacerbations, are more likely to be younger, have milder disease, and have fewer options for guideline-recommended treatment than those living in other global regions. Furthermore, Asian bronchiectasis patients demonstrate different comorbidities, microbiological profiles and unique endophenotypes, including post-tuberculosis and dry bronchiectasis. Notably, each Asian region reveals further geographic variations and inter-patient differences. Future studies are warranted to better characterise Asian patients with bronchiectasis.

Informations de copyright

Copyright ©The authors 2024.

Déclaration de conflit d'intérêts

Conflict of interest: H. Choi reports grant from the Basic Science Research Program of the Korean Ministry of Education (grant no. 2021R1I1A3052416); and consulting and lecture fees from Boryung Pharmaceutical Co., Ltd. and Kolon Pharma. J-F. Xu reports leadership or fiduciary roles in other boards, societies, committees, or advocacy groups (unpaid) with the Shanghai Medical Association, Chinese Thoracic Society, and Chinese Association of Chest Physicians. S.H. Chotirmall has served on advisory boards for CSL Behring, Pneumagen Ltd and Boehringer Ingelheim, on data monitoring boards for Inovio Pharmaceuticals and Imam Abdulrahman Bin Faisal University, and has received personal fees from AstraZeneca and Chiesi Farmaceutici, all unrelated to this work J.D. Chalmers reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Genentech, Gilead Sciences, GlaxoSmithKline, Grifols, Insmed, LifeArc and Novartis; and consulting fees from AstraZeneca, Chiesi, GlaxoSmithKline, Insmed, Grifols, Novartis, Boehringer Ingelheim, Pfizer, Janssen, Antabio and Zambon. L.C. Morgan reports payment or honoraria for speakers’ bureau from Boehringer Ingelheim, AstraZeneca and Insmed, and educational events from GSK Pharmaceutical and AstraZeneca, all unrelated to this work. In addition, L.C. Morgan reports a leadership or fiduciary role in other boards, societies, committees, or advocacy groups (unpaid) as Chair of the Lung Foundation Australia. R. Dhar reports grants from GSK Pharmaceutical and Glenmark and Thorasis; and lecture fees from Cipla Ltd., Lupin Respira, Glenmark, Abbott, Sanofi and AstraZeneca.